logo

ALXO

ALX Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ALXO fundamentals

ALX Oncology (ALXO) released its earnings on Nov 7, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.36 (YoY +20.00%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.36
+20.00%
Report date
Nov 7, 2025
ALXO Earnings Call Summary for Q3,2025
  • CD47 Biomarker Breakthrough: 65% ORR in CD47 high gastric cancer patients vs. 26% control, validating targeted IL-2 strategy.
  • Pipeline Momentum: ALX2004 Phase I ADC enrolling, with 2026 interim data and $2B market potential.
  • Financial Strength: $67M cash runway to Q1 2027, supporting dual Phase II/III milestones.
  • Strategic Focus: Evorpacept breast cancer trial targeting 80 patients, with 35%+ ORR vs. 20% control arm.
EPS
Revenue

Revenue & Expenses

Key Indicators

ALX Oncology (ALXO) key financial stats and ratios, covering profitability, financial health, and leverage.
ALX Oncology (ALXO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
ALX Oncology (ALXO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
ALX Oncology (ALXO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does ALX Oncology (ALXO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track ALX Oncology (ALXO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield